These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22233211)

  • 1. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
    Li C; Shen J; Wei X; Xie C; Lu W
    J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
    Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
    J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
    J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
    Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
    J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery.
    Zhan C; Meng Q; Li Q; Feng L; Zhu J; Lu W
    Chem Asian J; 2012 Jan; 7(1):91-6. PubMed ID: 22072592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
    Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W
    J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylene glycol-polylactic acid nanoparticles modified with cysteine-arginine-glutamic acid-lysine-alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect.
    Wu J; Zhao J; Zhang B; Qian Y; Gao H; Yu Y; Wei Y; Yang Z; Jiang X; Pang Z
    Int J Nanomedicine; 2014; 9():5261-71. PubMed ID: 25419130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes.
    Yang Y; Yan Z; Wei D; Zhong J; Liu L; Zhang L; Wang F; Wei X; Xie C; Lu W; He D
    Nanotechnology; 2013 Oct; 24(40):405101. PubMed ID: 24029287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
    Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
    Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
    Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
    Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.
    Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z
    Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Influencing the Immunogenicity and Immunotoxicity of Cyclic RGD Peptide-Modified Nanodrug Delivery Systems.
    Wang X; Meng N; Wang S; Lu L; Wang H; Zhan C; Burgess DJ; Lu W
    Mol Pharm; 2020 Sep; 17(9):3281-3290. PubMed ID: 32786957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes.
    Wang X; Meng N; Wang S; Zhang Y; Lu L; Wang R; Ruan H; Jiang K; Wang H; Ran D; Zhan C; Yu K; Burgess DJ; Lu W
    J Control Release; 2019 Dec; 316():381-392. PubMed ID: 31730912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.